Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Cost-Effectiveness Research Resource Center

Featured

News
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
Research Reports
04/12/2023
Poorni M. Manohar, MD
Kyle E. Bastys
Micah Tratt
Julie Gralow, MD, FACP, FASCO
Keith D. Eaton, MD, PhD
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the...
04/12/2023
Journal of Clinical Pathways
Manish Kohli
Videos
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
News
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Editor's Page
02/06/2023
Winston Wong, PharmD, Editor-in-Chief
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong, PharmD, outlines the Global Use of Medicines 2023 report on the next 5 years of medical spending and how the health care industry must continue to improve efficiency and quality, informed by evidence-based...
Editor-in-Chief, Winston Wong,...
02/06/2023
Journal of Clinical Pathways
Conference Coverage
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways

Advertisement

News

News
10/28/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
10/27/2023

Emry Lloyd

Emry Lloyd
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.
Katherine Baker, MD, and...
10/27/2023
Journal of Clinical Pathways
News
10/27/2023

Grace Taylor

Grace Taylor
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
10/26/2023

Brandon Twyford

Brandon Twyford
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact of the shift toward oral anti-cancer drugs and the consequent rise in costs within the Oncology Care Model. The abstract was presented at the 2023 ASCO Quality Care Symposium in Boston, Massachusetts.
Researchers examined the impact...
10/26/2023
Journal of Clinical Pathways
The role of cost in pathways panel discussion at CPC & CBEx 2023.
News
10/12/2023

Brandon Twyford

Brandon Twyford
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC & CBEx 2023 included a panel on “The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs,” where participants investigated factors beyond drug costs that affect the bottom line...
Sunday’s day of sessions at CPC...
10/12/2023
Journal of Clinical Pathways
News
02/14/2023

Yvette C Terrie

Yvette C Terrie
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
01/30/2023

Grace Taylor

Grace Taylor
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.
In a cost analysis presented at...
01/30/2023
Journal of Clinical Pathways
Conference Coverage
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
03/20/2024

Brandon Twyford

Brandon Twyford
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the...
03/20/2024
Journal of Clinical Pathways
News
03/19/2024

Grace Taylor

Grace Taylor
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.
Eric Rios-Doria, MD, and...
03/19/2024
Journal of Clinical Pathways
News
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
News
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
03/17/2024

Allison Casey

Allison Casey
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial,...
03/17/2024
Oncology

Videos

Manish Kohli
Videos
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Kishan Patel, MD, Yale School of Medicine
Videos
07/01/2021
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.
Kishan Patel, MD, discusses...
07/01/2021
Journal of Clinical Pathways
Videos
06/10/2021
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Briana Choi, PharmD, discusses...
06/10/2021
Journal of Clinical Pathways
David Barrington, MD
Videos
06/10/2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses...
06/10/2021
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Nate Wade, PharmD.
Videos
03/25/2024

Featuring Nade Wade, PharmD, MBA, BCOP

Featuring Nade Wade, PharmD, MBA, BCO...
In this video interview, Nade Wade, PharmD, MBA, BCOP, associate director for clinical oncology at Flatiron Health, talks about the role of electronic health records in precision medicine.
In this video interview, Nade Wade, PharmD, MBA, BCOP, associate director for clinical oncology at Flatiron Health, talks about the role of electronic health records in precision medicine.
In this video interview, Nade...
03/25/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Jing-Zhou Hou, MD, PhD
Videos
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Brian M. Slomovitz, MD
Conference Coverage
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
BDHC thumbnail
Breaking Down Health Care
03/18/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In this first installment of the Breaking Down Health Care video series, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the fundamentals of how health care works in the United States, including covering the main payers, to set the...
In this first installment of the Breaking Down Health Care video series, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the fundamentals of how health care works in the United States, including covering the main payers, to set the...
In this first installment of the...
03/18/2024
Cancer Care Business Exchange
David Cibula, MD, PhD
Conference Coverage
03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting,...
03/17/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Video thumbnail screenshot.
Videos
03/11/2024

Featuring Barbara McAneny, MD, and Sibel Blau, MD

Featuring Barbara McAneny, MD, and Si...
Longtime industry leaders Barbara McAneny, MD, and Sibel Blau, MD, have joined forces to create ONCare Alliance, a strategic collaboration that aims to redefine the independent practice in community cancer care.
Longtime industry leaders Barbara McAneny, MD, and Sibel Blau, MD, have joined forces to create ONCare Alliance, a strategic collaboration that aims to redefine the independent practice in community cancer care.
Longtime industry leaders...
03/11/2024
Cancer Care Business Exchange

Advertisement

Advertisement

Advertisement